SCHEMBL4059720

SCHEMBL4059720

C(=C/c1nc2ncc(-c3ccco3)cc2[nH]1)\c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.44
ALDH1A1 P00352 5/20 0.44
RAB9A P51151 5/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
KDM4E B2RXH2 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
PKM P14618 2/20 0.44
HPGD P15428 2/20 0.44
HSP90AA1 P07900 1/20 0.44
MAPK1 P28482 2/20 0.40
TRPV1 Q8NER1 1/20 0.39
MAPT P10636 4/20 0.38
ATM Q13315 1/20 0.38
TUBB4A P04350 6/20 0.37
TUBB P07437 6/20 0.37
TUBA3C P0DPH7 6/20 0.37
TUBA1B P68363 6/20 0.37
TUBA4A P68366 6/20 0.37
TUBB4B P68371 6/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4059729 1.00 NPC1 (0.44) NPC1ALDH1A1RAB9AMEN1KMT2A
SCHEMBL4056638 0.83 NPC1 (0.51) NPC1ALDH1A1RAB9AMEN1KMT2A
SCHEMBL4056642 0.83 NPC1 (0.51) NPC1ALDH1A1RAB9AMEN1KMT2A
SCHEMBL13608043 0.81 MEN1 (0.44) NPC1ALDH1A1RAB9AMEN1KMT2A
SCHEMBL4055727 0.79 NPC1 (0.55) NPC1ALDH1A1RAB9AMEN1KMT2A
SCHEMBL4055724 0.79 NPC1 (0.55) NPC1ALDH1A1RAB9AMEN1KMT2A
SCHEMBL4050957 0.79 IKBKE (0.49) NPC1ALDH1A1RAB9AKDM4ESMN1; SMN2
SCHEMBL4060113 0.77 NPC1 (0.45) NPC1ALDH1A1RAB9AMEN1KMT2A
SCHEMBL4060105 0.77 NPC1 (0.45) NPC1ALDH1A1RAB9AMEN1KMT2A
SCHEMBL4056022 0.76 NPC1 (0.44) NPC1ALDH1A1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NPC1 4740/4885ALDH1A1 3683/4885RAB9A 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.